Real-world pan-tumor comprehensive genomic profiling sample adequacy and success rates in tissue and liquid specimens.

IF 4.8 2区 医学 Q1 ONCOLOGY Oncologist Pub Date : 2025-02-06 DOI:10.1093/oncolo/oyae258
Douglas I Lin, Lincoln W Pasquina, Estefany Mavares, Julia A Elvin, Richard S P Huang
{"title":"Real-world pan-tumor comprehensive genomic profiling sample adequacy and success rates in tissue and liquid specimens.","authors":"Douglas I Lin, Lincoln W Pasquina, Estefany Mavares, Julia A Elvin, Richard S P Huang","doi":"10.1093/oncolo/oyae258","DOIUrl":null,"url":null,"abstract":"<p><p>Real-world success rate of liquid and tissue-based comprehensive genomic profiling (CGP) is unknown. We analyzed real-world pan-tumor cohorts that underwent CGP during clinical care via FoundationOne CDx (F1CDx) and FoundationOne Liquid CDx (F1LCDx) to determine tissue and liquid sample adequacy based on tumor type. Pan-tumor presequencing adequacy was high (>90%) by both tissue-based F1CDx (median: 92.3%; range: 88.2%-96.9%) and liquid-based F1LCDx (median: 94.8%; range: 86.6%-96.7%). Similarly, postsequencing analysis revealed that most tissue and liquid samples yielded successful sequencing results with a median sequencing success rate of 97.9% and 98.1% for F1CDx and F1LCDx, respectively. One exception is central nervous system (CNS) tumors, for which F1CDx had dramatically higher sample sufficiency (96.9%) and postsequencing success rate (97.0%) compared with F1LCDx (86.6% and 92.9%, respectively). The pan-tumor median sample-to-success rate was 90.4% (range: 84.8%-94.4%) for F1CDx. The equivalent rate for F1LCDx was slightly higher at 93.2% (range: 80.4%-95.7%). Conversely, when examining the prevalence of F1LCDx results with high tumor fraction (TF≥1%), the sample-to-high TF results rate was dramatically lower (median: 37.7%, range: 2.1% [CNS tumors]-46.0%). In conclusion, except in CNS tumors or when accounting for liquid TF, success rates of F1CDx and F1LCDx are equivalently high. These results may guide informed decision on when to pursue tissue vs liquid testing of patients with cancer.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881061/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyae258","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Real-world success rate of liquid and tissue-based comprehensive genomic profiling (CGP) is unknown. We analyzed real-world pan-tumor cohorts that underwent CGP during clinical care via FoundationOne CDx (F1CDx) and FoundationOne Liquid CDx (F1LCDx) to determine tissue and liquid sample adequacy based on tumor type. Pan-tumor presequencing adequacy was high (>90%) by both tissue-based F1CDx (median: 92.3%; range: 88.2%-96.9%) and liquid-based F1LCDx (median: 94.8%; range: 86.6%-96.7%). Similarly, postsequencing analysis revealed that most tissue and liquid samples yielded successful sequencing results with a median sequencing success rate of 97.9% and 98.1% for F1CDx and F1LCDx, respectively. One exception is central nervous system (CNS) tumors, for which F1CDx had dramatically higher sample sufficiency (96.9%) and postsequencing success rate (97.0%) compared with F1LCDx (86.6% and 92.9%, respectively). The pan-tumor median sample-to-success rate was 90.4% (range: 84.8%-94.4%) for F1CDx. The equivalent rate for F1LCDx was slightly higher at 93.2% (range: 80.4%-95.7%). Conversely, when examining the prevalence of F1LCDx results with high tumor fraction (TF≥1%), the sample-to-high TF results rate was dramatically lower (median: 37.7%, range: 2.1% [CNS tumors]-46.0%). In conclusion, except in CNS tumors or when accounting for liquid TF, success rates of F1CDx and F1LCDx are equivalently high. These results may guide informed decision on when to pursue tissue vs liquid testing of patients with cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
真实世界泛肿瘤综合基因组图谱样本的充分性和组织与液体标本的成功率。
基于液体和组织的全面基因组分析(CGP)的实际成功率尚不清楚。我们分析了在临床治疗期间通过FoundationOne CDx(F1CDx)和FoundationOne Liquid CDx(F1LCDx)进行CGP的真实世界泛肿瘤队列,以确定基于肿瘤类型的组织和液体样本的充分性。基于组织的 F1CDx(中位数:92.3%;范围:88.2%-96.9%)和基于液体的 F1LCDx(中位数:94.8%;范围:86.6%-96.7%)的泛肿瘤前测序充分性都很高(>90%)。同样,测序后分析表明,大多数组织和液体样本都获得了成功的测序结果,F1CDx 和 F1LCDx 的中位测序成功率分别为 97.9% 和 98.1%。但中枢神经系统(CNS)肿瘤是个例外,与 F1LCDx(分别为 86.6% 和 92.9%)相比,F1CDx 的样本充分率(96.9%)和测序后成功率(97.0%)大幅提高。F1CDx的泛肿瘤中位样本成功率为90.4%(范围:84.8%-94.4%)。F1LCDx 的相应比率略高,为 93.2%(范围:80.4%-95.7%)。相反,当检查高肿瘤分数(TF≥1%)的 F1LCDx 结果的流行率时,样本到高 TF 结果的比率大幅降低(中位数:37.7%,范围:2.1% [中枢神经系统肿瘤]-46.0%)。总之,除中枢神经系统肿瘤或考虑液体 TF 外,F1CDx 和 F1LCDx 的成功率相当高。这些结果可以指导人们做出明智的决定,决定何时对癌症患者进行组织检验和液体检验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncologist
Oncologist 医学-肿瘤学
CiteScore
10.40
自引率
3.40%
发文量
309
审稿时长
3-8 weeks
期刊介绍: The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
期刊最新文献
"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype. Classification of NK-large granular lymphocytic leukemia by CD56 expression. Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma. Managing elderly patients with dual metastatic cancers-navigating diagnostic and treatment challenges. Prognostic relevance of immunoglobulin heavy chain rearrangement and immunoglobulin kappa light chain rearrangement in patients with diffuse large B cell lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1